Despite promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from pharmacy benefit managers. Such organizations are frequently building limitations to reimbursement, like significant price restrictions and prior authorization that hinder consumer opp